Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Phase 2 Completed 25 enrolled Philogen S.p.A.

NaSingle-groupOpen-labelTreatment

Summary

Phase II, non-randomized, multicenter, prospective study designed to test the efficacy and safety of intratumorally administered L19IL2 in patients suffering from metastatic melanoma.

Timeline

Start: 2010-04
Primary completion: 2013-09
Completion: 2013-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Darleukin	Protein / enzyme biologic	2e+07 iu	Other

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Summary

Timeline

Drugs

Indications